Probe of Alzheimer's studies finds 'egregious misconduct'.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Piller C
  • Source:
    Science (New York, N.Y.) [Science] 2023 Oct 20; Vol. 382 (6668), pp. 251-252. Date of Electronic Publication: 2023 Oct 19.
  • Publication Type:
    News
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE
    • Publication Information:
      Publication: : Washington, DC : American Association for the Advancement of Science
      Original Publication: New York, N.Y. : [s.n.] 1880-
    • Subject Terms:
      Alzheimer Disease*/prevention & control ; Spiro Compounds* ; Scientific Misconduct*; Humans ; Biotechnology ; United States
    • Abstract:
      Co-developer of biotech's drug couldn't supply original data.
    • Accession Number:
      6NV440YIO0 (Simufilam)
      0 (Spiro Compounds)
    • Publication Date:
      Date Created: 20231019 Date Completed: 20231024 Latest Revision: 20231027
    • Publication Date:
      20231215
    • Accession Number:
      10.1126/science.adl4276
    • Accession Number:
      37856608